DRUG
Teriparatide
Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both "patients" and "controls"
Status
Completed
Phase
Not applicable
Enrollment
20
Locations
1
Results
Posted
Publications
1
Study summary
The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.
Vitamin D, an essential nutrient, is produced by the skin after sunlight shines on it. Vitamin D must then be activated by both the liver and the kidneys to perform its function of maintaining strong bones and helping to prevent heart disease, infection, diabetes and cancer. Reduced kidney activation of Vitamin D occurs with advanced age and with all kidney diseases. We have identified a small group of patients who appear to have reduced ability of the kidneys to activate vitamin D, even though they are young and do not have chronic kidney disease. In these patients, we are comparing the ability of their kidneys to activate Vitamin D to that of healthy controls. To stimulate the kidneys to activate Vitamin D, we are giving parathyroid hormone intravenously over 8 hours and collecting blood and urine at baseline, 4 and 8 hours. This type of parathyroid infusion does not cause side effects. The gene that controls this activation is also being studied (by a simple blood test) to look for abnormalities. We are now actively recruiting healthy controls for this study.
Interventions
DRUG
Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both "patients" and "controls"
Timeline
First posted
Sep 18, 2008
Study start
Feb 2007
Primary completion
Aug 2008
Study completion
Aug 2008
Results posted
May 14, 2014
Registry updated
Apr 1, 2022
Outcomes
The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours
Time frame · baseline, 4 and 8 hours after start of infusion
1,25-D was measured at baseline, 4 and 8 hours after PTH infusion
The Number of Patients With Mutations in CYP27B1
Time frame · blood samples taken at baseline and sequenced over several days
CYP27B1 gene (the gene for 25-hydroxyvitamin D-1-alpha hydroxylase) was sequenced for all in patient group and compared with published control data
Eligibility
Inclusion Criteria: * Caucasian female * Age 40-59 years * Serum creatinine \< 1.3 and estimated glomerular filtration rate (GRF) \> 60 * Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl) * Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml) * Normal 25-hydroxyvitamin D level (30 ng/ml or higher) * For women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion) Exclusion Criteria: * Non-caucasian * Age under 40 and over 59 years * Male * Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) \< 60 * Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl) * Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml) * For women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion) * History of bone radiation * History of Paget disease of bone * History of bone malignancy or metastases * History of allergy or sensitivity to Forteo
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
University of Maryland School of Medicine Division of Endocrinology
Baltimore, Maryland, United States
Related trials
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.